immunotherapy

Weekly Recap: 12 Tech Press Releases You Need to See

A roundup of the most newsworthy tech announcements from PR Newswire this week, including the release of VERA-MH by Spring Health…

1 month ago

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF),…

1 month ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

SAN JOSE, Calif., Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company…

1 month ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment.…

2 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast…

2 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™…

2 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will…

2 months ago

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of…

2 months ago

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in…

2 months ago

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses…

2 months ago